Interaction of Morphine With a New α2-Adrenoceptor Agonist in Mice
Received 9 March 2009; received in revised form 8 July 2009; accepted 4 August 2009. published online 23 October 2009.
Abstract
Finding new chemicals or adjuvants with analgesic effects in the central nervous system is clinically relevant due to the limited number of drugs with these properties. Here, we present PT-31, which is chemically related to 3-benzyl-imidazolidine, with an analgesic profile that results from α2-adrenoceptor activation. Intraperitoneal administration of PT-31 dose-dependently produced antinociception in the hot plate test, and interacted synergistically with morphine. This effect was completely reversed by yohimbine, a non-selective antagonist of α2-adrenoceptors, and by BRL 44408, a selective α2A-adrenoceptor antagonist. The combination of morphine and PT-31 produced greater antinociceptive activity than either alone, and isobolographic analysis revealed a synergistic interaction between these compounds. Docking results confirm the high affinity of the PT-31 ligand at the α2A-adrenoceptor.
Perspective
This study introduces a new analgesic compound (PT-31) that acts via α2A-adrenoceptor activation. A significant increase in analgesia was observed when co-administered with morphine. PT-31 is an interesting new substance for pain therapy.
∗Programa de Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil
†Serviço de Anestesiologia e Programa de Pós-Gradução em Medicina (Cirurgia), Universidade Federal do Rio de Janeiro, Brazil
‡Núcleo de Pesquisa em Inovação Terapêutica, Universidade Federal de Pernambuco, Brazil
Address reprint requests to Dr. Roberto T. Sudo, Programa de Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Bloco J, Sala 14, Rio de Janeiro, Brazil, CEP 21941-590.
Supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnológico (CNPq, BR), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, BR), Fundação Universitária Jose Bonifácio (FUJB, BR), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ, BR) and Instituto do Milênio: Inovação e Desenvolvimento de Fármacos e Medicamentos – IM-INOFAR for finantial support and fellowships.